Profile data is unavailable for this security.
About the company
Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas. It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination. It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.24m
- Incorporated2021
- Employees7.00
- LocationOxford Cannabinoid Technologies Holdings PLCPrama House, 267 Banbury RoadOXFORD OX2 7HTUnited KingdomGBR
- Phone+44 20 3034 2820
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Ovoca Bio PLC | 0.00 | -2.00m |
| Voyager Life PLC | 314.00k | -1.10m |
| Nuformix PLC | 0.00 | -436.95k |
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m |
| ReNeuron Group Plc | 249.00k | -5.07m |
| N4 Pharma PLC | 1.95k | -1.28m |
| Hellenic Dynamics PLC | -100.00bn | -100.00bn |
| ValiRx Plc | 9.60k | -2.04m |
| TheraCryf PLC | 838.00k | -3.35m |
| Fusion Antibodies PLC | 1.58m | -2.84m |
| IXICO PLC | 6.67m | -1.18m |
| BSF Enterprise PLC | 12.94k | -1.50m |
